Flinn Raises $20M To Expand AI Solutions For MedTech And Pharma Product Management

The round was led by HV Capital, with participation from US healthcare investor BHI – Bertelsmann Healthcare Investments, and continued support from existing backers Cherry Ventures, Speedinvest, and SquareOne.

The funding arrives as healthcare systems globally grapple with ageing populations, complex treatments and administrative pressures that strain public budgets and may restrict patient access to care.

While medical devices and pharmaceuticals enhance efficiency with automation advanced diagnostics and personalised treatments strict regulatory and quality standards can extend development timelines and increase costs.

Flinn addresses these challenges with AI powered software that automates regulatory workflows data analysis and reporting, replacing manual document-heavy processes with scalable efficient solutions.

Read Also- Copla Secures €6M Series A To Boost EU Regulatory Compliance

Founded in 2022 the company is driven by a mission to improve global health, combining a customer-focused, experimentation-driven approach with AI-powered solutions to streamline compliance and product development.

Bastian Krapinger-Rüther, Co-founder and Co-CEO of Flinn, said regulatory and quality requirements are increasingly contributing to costs across the medical product lifecycle.

Our software replaces manual, document-heavy workflows with automated systems that scale across products, markets and regulatory regimes. This additional investment enables us to extend that infrastructure across more lifecycle stages and support manufacturers operating globally, he added.

Flinn’s platform leverages automation in regulatory and quality processes to help MedTech manufacturers increase operational efficiency, speed up development timelines and stay compliant while ensuring patient safety. By reducing administrative workloads, it allows teams to concentrate more on innovation and advancing product development.

With the new funding, Flinn plans to extend its platform to cover earlier development stages and commercial processes, creating a unified compliance and quality framework across the full medical product lifecycle.

The company will also use the capital to fuel international growth, expanding further across Europe and entering the US market.

About Flinn

Flinn.ai empowers MedTech companies to automate regulatory and quality processes, helping them launch and operate products up to 10x more efficiently. Founded in 2022 the company is driven by a mission to improve global health, combining a customer-focused, experimentation-driven approach with AI-powered solutions to streamline compliance and product development.